196 related articles for article (PubMed ID: 31043700)
1. JOSD1 inhibits mitochondrial apoptotic signalling to drive acquired chemoresistance in gynaecological cancer by stabilizing MCL1.
Wu X; Luo Q; Zhao P; Chang W; Wang Y; Shu T; Ding F; Li B; Liu Z
Cell Death Differ; 2020 Jan; 27(1):55-70. PubMed ID: 31043700
[TBL] [Abstract][Full Text] [Related]
2. The deubiquitinating enzyme USP20 regulates the stability of the MCL1 protein.
Feng J; Liu P; Li X; Zhang D; Lin H; Hou Z; Guo C; Niu Y; Dai B; Wang O; Qi M; Wang H; Zhou H
Biochem Biophys Res Commun; 2022 Feb; 593():122-128. PubMed ID: 35063767
[TBL] [Abstract][Full Text] [Related]
3. JOSD1 promotes proliferation and chemoresistance of head and neck squamous cell carcinoma under the epigenetic regulation of BRD4.
Jing C; Liu D; Lai Q; Li L; Zhou M; Ye B; Wu Y; Li H; Yue K; Wu Y; Duan Y; Wang X
Cancer Cell Int; 2021 Jul; 21(1):375. PubMed ID: 34261480
[TBL] [Abstract][Full Text] [Related]
4. MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer.
Wu X; Luo Q; Zhao P; Chang W; Wang Y; Shu T; Ding F; Li B; Liu Z
Proc Natl Acad Sci U S A; 2019 Feb; 116(8):2961-2966. PubMed ID: 30718431
[TBL] [Abstract][Full Text] [Related]
5. Interplay between protein acetylation and ubiquitination controls MCL1 protein stability.
Shimizu K; Gi M; Suzuki S; North BJ; Watahiki A; Fukumoto S; Asara JM; Tokunaga F; Wei W; Inuzuka H
Cell Rep; 2021 Nov; 37(6):109988. PubMed ID: 34758305
[TBL] [Abstract][Full Text] [Related]
6. Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors.
Zhang S; Zhang M; Jing Y; Yin X; Ma P; Zhang Z; Wang X; Di W; Zhuang G
Nat Commun; 2018 Jan; 9(1):215. PubMed ID: 29335437
[TBL] [Abstract][Full Text] [Related]
7. Death domain-associated protein DAXX promotes ovarian cancer development and chemoresistance.
Pan WW; Zhou JJ; Liu XM; Xu Y; Guo LJ; Yu C; Shi QH; Fan HY
J Biol Chem; 2013 May; 288(19):13620-30. PubMed ID: 23539629
[TBL] [Abstract][Full Text] [Related]
8. NF1 regulates apoptosis in ovarian cancer cells by targeting MCL1 via miR-142-5p.
Su J; Ruan S; Dai S; Mi J; Chen W; Jiang S
Pharmacogenomics; 2019 Feb; 20(3):155-165. PubMed ID: 30543142
[TBL] [Abstract][Full Text] [Related]
9. MCL1 regulates cell death, tumor growth and chemosensitivity to sabutoclax in ovarian adenocarcinoma.
Li C; Song Y; Li P
Cell Tissue Res; 2020 Mar; 379(3):625-633. PubMed ID: 31754782
[TBL] [Abstract][Full Text] [Related]
10. Deubiquitinase JOSD1 promotes tumor progression via stabilizing Snail in lung adenocarcinoma.
Ma X; Qi W; Yang F; Pan H
Am J Cancer Res; 2022; 12(5):2323-2336. PubMed ID: 35693075
[TBL] [Abstract][Full Text] [Related]
11. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
[No Abstract] [Full Text] [Related]
12. miR-153-3p regulates progression of ovarian carcinoma in vitro and in vivo by targeting MCL1 gene.
Li C; Zhang Y; Zhao W; Cui S; Song Y
J Cell Biochem; 2019 Nov; 120(11):19147-19158. PubMed ID: 31297886
[TBL] [Abstract][Full Text] [Related]
13. MKNK2 enhances chemoresistance of ovarian cancer by suppressing autophagy via miR-125b.
Wang J; Da C; Su Y; Song R; Bai Z
Biochem Biophys Res Commun; 2021 Jun; 556():31-38. PubMed ID: 33836345
[TBL] [Abstract][Full Text] [Related]
14. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
15. MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells.
Zarogoulidis P; Petanidis S; Kioseoglou E; Domvri K; Anestakis D; Zarogoulidis K
Cell Signal; 2015 Aug; 27(8):1576-88. PubMed ID: 25917317
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options.
Wu X; Luo Q; Liu Z
Cell Death Dis; 2020 Jul; 11(7):556. PubMed ID: 32699213
[TBL] [Abstract][Full Text] [Related]
17. Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation.
Zhang M; Cong Q; Zhang XY; Zhang MX; Lu YY; Xu CJ
J Cell Physiol; 2019 May; 234(5):6361-6370. PubMed ID: 30229902
[TBL] [Abstract][Full Text] [Related]
18. ApoG2 inhibits the antiapoptotic protein, Mcl‑1, and induces mitochondria‑dependent apoptosis in human colorectal cancer cells.
Li T; Yuan G; Zhang L; Ye L; Li S; Fan Y; Sun J
Mol Med Rep; 2015 Nov; 12(5):6976-84. PubMed ID: 26352605
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of mitochondrial translation as a therapeutic strategy for human ovarian cancer to overcome chemoresistance.
Hu B; Guo Y
Biochem Biophys Res Commun; 2019 Feb; 509(2):373-378. PubMed ID: 30591219
[TBL] [Abstract][Full Text] [Related]
20. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.
Li X; Chen W; Jin Y; Xue R; Su J; Mu Z; Li J; Jiang S
Biochem Pharmacol; 2019 Mar; 161():98-112. PubMed ID: 30639456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
